FOR IMMEDIATE RELEASE
OmniComm Systems® Signs 5-Year, Multi-Million Dollar TrialMaster® EDC Agreement with Major CRO
This deal highlights a strong H1 2015 with net revenue growth of 42% YOY
Fort Lauderdale, FL, September 22, 2015 - OmniComm Systems, Inc. (OmniComm) (OTCQX: OMCM), a global leading provider of clinical data management technology, today announced a five year, multi-million dollar agreement with a leading contract research organization (CRO) for OmniComm’s TrialMaster electronic data capture technology (EDC).
Ranked within the top 5 CROs for excellence in clinical monitoring and clinical research, this CRO selected TrialMaster to meet their current and future data management requirements for their expanding number of Phase I through Phase IV clinical studies.
TrialMaster was selected for its inherent flexibility, scalability and broad capabilities to support clinical studies across all phases of clinical development. The latest release of TrialMaster includes over 300 new innovative productivity and functionality enhancements. Deploying studies in an efficient, timely and cost effective manner was especially important to the CRO as well as the speed of knowledge transfer for self-reliance. OmniComm’s dedication to EDC product development, as well as our robust, state-of-the art compliant hosting environment was critical in their selection process.
“Today, our specialized EDC technologies offer unique features that help CROs deliver far greater benefits to their clients in terms of better business insight, quality, timeliness and cost,” said Kuno van der Post, SVP of business development, OmniComm. “Our CRO partners are now using these strengths to successfully differentiate themselves in the sales cycle against those other CROs offering older, weakly developed and less functionally rich systems.”
“We are pleased with the addition of yet another leading CRO to our client list. This deal highlights another great first half for us – one in which we’ve seen 42% year-over-year growth in our revenue compared to the first half of 2014,” stated Stephen Johnson, president and COO of OmniComm Systems. “We are focused not only on growing revenue but also controlling operating and overhead expenses for the remainder of FY 2015.”
Supporting Information
OmniComm Systems Announces Innovative New Release of TrialMaster® EDC
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.